Back
Compare AU
Compare BNDS vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares Western Asset Aus Bond Active ETF (BNDS) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
BNDS | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 18 | 69 |
Median incremental investment | $755.50 | $665.63 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,028.72 | $1,925.44 |
Average age group | > 35 | > 35 |
Key Summary
BNDS | CURE | |
|---|---|---|
Strategy | BNDS.AX was created on 2018-11-07 by BetaShares. The fund's investment portfolio concentrates primarily on broad credit fixed income. The Fund aims to earn an after fee return in excess of the Bloomberg AusBond Composite 0+yr Index over rolling three year periods. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | AUSTRALIAN GOVERNMENT 3.5% DEC-34 (2.10 %) AUSTRALIAN GOVERNMENT 2.75% MAY-41 (1.65 %) AUSTRALIAN GOVERNMENT 3.75% MAY-34 (1.46 %) | Moderna Inc (1.76 %) Vaxcyte Inc Ordinary Shares (1.58 %) Mirum Pharmaceuticals Inc (1.56 %) |
Top 3 industries | Other (99.56 %) Communication Services (0.44 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (96.62 %) United Kingdom of Great Britain and Northern Ireland (1.35 %) Switzerland (1.13 %) | |
Management fee | 0.42 % | 0.45 % |
Key Summary
BNDS | CURE | |
|---|---|---|
Issuer | BetaShares | Global X |
Tracking index | Bloomberg AusBond Composite Index - AUD | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.42 % | 0.45 % |
Price | $23.46 | $59.03 |
Size | $834.780 million | $39.944 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 2.20 % | 5.08 % |
Market | ASX | ASX |
First listed date | 16/11/2018 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
BNDS | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 18 | 69 |
Median incremental investment | $755.50 | $665.63 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,028.72 | $1,925.44 |
Average age group | > 35 | > 35 |
Pros and Cons
BNDS | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
BNDS | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |